Type-specific duration of human papillomavirus infection: Implications for human papillomavirus screening and vaccination

Journal of Infectious Diseases

Volumn 197, Issue 10, 2008, Pages 1436-1447

  Trottier, Helen ^a   Mahmud, Salaheddin ^a,b   Prado, José Carlos M ^c   Sobrinho, Joao S ^c   Costa, Maria C ^c   Rohan, Thomas E ^a,d   Villa, Luisa L ^c   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; AGE; ARTICLE; BRAZIL; CANCER SCREENING; COHORT ANALYSIS; DISEASE DURATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MIXED INFECTION; PHYLOGENY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SEROTYPE; SEXUALITY; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; CERVIX UTERI; COHORT STUDIES; COMORBIDITY; DNA, VIRAL; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; SEXUAL BEHAVIOR; TIME FACTORS;

EID: 43949129406     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/587698     Document Type: Article

References (44)

1. International Agency for Research on Cancer (IARC) Working Group. Human papillomaviruses. Lyon, France: IARC, 1995:277-82. IARC monographs on the evaluation of carcinogenic risks to human, vol. 64.
2. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88:63-73.
3. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
4. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 2003; 127:930-4.
5. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999; 91:954-60.
6. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286:3106-14.
7. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325(7364):572.
8. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-84.
9. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180:1415-23.
10. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831-6.
11. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002; 186:462-9.
12. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12:485-90.
13. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190:2077-87.
14. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191:182-92.
15. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235-40.
16. Kotloff KL, Wasserman SS, Russ K, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 1998; 25:243-50.
17. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8.
18. Xi LF, Carter JJ, Galloway DA, et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 2002; 11:343-51.
19. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158:486-94.
20. Koshiol JE, Schroeder JC, Jamieson DJ, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006; 119:1623-9.
21. Syrjanen S, Shabalova I, Petrovichev N, et al. Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union. Int J STD AIDS 2005; 16:217-23.
22. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007; 16:709-15.
23. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Rev Panam Salud Publica 1999; 6:223-33.
24. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991; 265:472-7.
25. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-61.
26. International Agency for Research on Cancer (IARC). Human papillomaviruses. Lyon, France: IARC, 2007. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 90.
27. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
28. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94:1406-14.
29. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1796-807.
30. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285:2995-3002.
31. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190:37-45.
32. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-26.
33. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24(Suppl 1):S1-15.
34. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582-9.
35. Brisson J, Bairati I, Morin C, et al. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis 1996; 173:794-9.
36. Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000; 183:561-7.
37. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808-16.
38. Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005; 14:1149-56.
39. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682-90.
40. Syrjanen S, Shabalova I, Petrovichev N, et al. Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union. Eur J Gynaecol Oncol 2005; 26:491-8.
41. Wang SS, Schiffman M, Herrero R, et al. Determinants of human papillomavirus 16 serological conversion and persistence in a populationbased cohort of 10 000 women in Costa Rica. Br J Cancer 2004; 91:1269-74.
42. Perrons C, Jelley R, Kleter B, Quint W, Brink N. Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J Clin Virol 2005; 32:278-85.
43. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183:8-15.
44. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15:1274-80.